A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice

Biochimica et Biophysica Acta - General Subjects

Volumn 1725, Issue 2, 2005, Pages 182-189

  Nikou, Konstantina N ^a,b   Stivaktakis, Nikolaos ^b   Avgoustakis, Konstantinos ^b   Sotiropoulou, Panagiota A ^c   Perez, Sonia A ^c   Baxevanis, Constantin N ^c   Papamichail, Michael ^c   Leondiadis, Leondios ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Cancer; HER 2 neu; Immune response; Peptide; PLA microsphere; Vaccine

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FREUND ADJUVANT; MICROSPHERE; POLYLACTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG PURIFICATION; DRUG SYNTHESIS; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUPERNATANT; TH1 CELL; TRANSGENIC MOUSE;

ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; DIFFUSION; DRUG CARRIERS; EPITOPES; IMMUNIZATION; MATERIALS TESTING; MICE; MICROSPHERES; PEPTIDE FRAGMENTS; POLYESTERS; PROTEIN BINDING; RECEPTOR, ERBB-2; TH1 CELLS; VACCINES;

ANIMALIA; MUS MUSCULUS;

EID: 24344445499     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2005.07.004     Document Type: Article

References (53)

1. C.G. Ioannides, C.D. Platsoucas, C.A. O'Brian, R. Patenia, J.M. Bowen, J.T. Wharton, and R.S. Freedman Viral oncolysates in cancer treatment: immunological mechanisms of action Anticancer Res. 9 1989 535 544
2. N. Poloso, S. Nagarajan, G.W. Bumgarner, J.C. Zampell, and P. Selvaraj Designer cancer vaccines made easy: protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines Front Biosci. 6 2001 D760 D775
3. R. Sundaram, N.K. Dakappagari, and P.T. Kaumaya Synthetic peptides as cancer vaccines Biopolymers 66 2002 200 216
4. N.M. Haynes, J.A. Trapani, M.W.L. Teng, J.T. Jackson, L. Cerruti, S.M. Jane, M.H. Kershaw, M. Smyth, and P.K. Darcy Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 100 2002 3155 3163
5. Y. Yamanaka, H. Friess, M.S. Kobrin, M. Buchler, J. Kunz, H.G. Beger, and M. Korc Overexpression of HER-2/neu proto-oncogene in human pancreatic carcinoma Hum. Pathol. 24 1993 1127 1134
6. I. Yoshino, P.S. Goedegebuure, G.E. Peoples, A.S. Parikh, J.M. DiMaio, H.K. Lyerty, A.F. Gazdar, and T.J. Eberlein HER-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer Cancer Res. 54 1994 3387 3390
7. M. Peiper, P.S. Goedegebuure, D.C. Linehan, E. Ganguly, C.C. Douville, and T.J. Eberlein The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes Eur. J. Immunol. 27 1997 1115 1123
8. P. Brossart, G. Stuhler, T. Flad, S. Stevanovic, H.G. Rammensee, L. Kanz, and W. Brugger Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes Cancer Res. 58 1998 732 736
9. C.A. Maxwell-Armstrong, L.G. Durrant, and J.H. Scholefield Colorectal cancer vaccines Br. J. Surg. 85 1998 149 154
10. H.I. Scher HER2 in prostate cancer-A viable target or innocent bystander? J. Natl. Cancer Inst. 92 2000 1866 1868
11. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
12. M.C. Hung, and Y.K. Lau Basic science of HER-2/neu: a review Semin. Oncol. 26 1999 51 59
13. C.N. Baxevanis, A.D. Gritzapis, O.E. Tsitsilonis, H.L. Katsoulas, and M. Papamichail HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes Int. J. Cancer 98 2002 864 872
14. K. Kono, Y. Rongcun, J. Charo, F. Ichihara, E. Celis, A. Sette, E. Appellia, T. Sekikawa, Y. Matsumoto, and R. Kiessling Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes Int. J. Cancer 78 1998 202 208
15. Y. Rongcun, F. Salazar-Onfray, J. Charo, K.J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, L. Lan, E. Appella, A. Sette, E. Celis, and R. Kiessling Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas J. Immunol. 163 1999 1037 1044
16. S.A. Perez, P.A. Sotiropoulou, N.N. Sotiriadou, A. Mamalaki, A.D. Gritzapis, H. Echner, V. Voelter, G. Pawelec, M. Papamichail, and C.N. Baxevanis HER-2/neu derived peptide 884-899 is expressed in human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones Cancer Immunol. Immunother. 50 2002 615 624
17. R. Sotiriadou, S.A. Perez, A.D. Gritzapis, P.A. Sotiropoulou, H. Echner, S. Heinzel, A. Mamalaki, G. Pawelec, W. Voelter, C.N. Baxevanis, and M. Papamichail Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope Br. J. Cancer 85 2001 1527 1534
18. R. Mayer, C. Ioannides, T. Moran, B. Johansson, and C. Bona Effect of syngeneic anti-idiotypic antibody on influenza virus neuraminidase antibody response Viral Immunol. 1 1987 121 134
19. M. Kuiper, M. Peakman, and F. Farzaneh Ovarian tumour antigens as potential targets for immune gene therapy Gene Ther. 2 1995 7 15
20. T.M. Foy, J. Bannink, R.A. Sutherland, P.D. McNeill, G.G. Moulton, J. Smith, M.A. Cheever, and K. Grabstein Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor Vaccine 19 2001 2598 2606
21. M.L. Disis, K.H. Grabstein, D.R. Sleath, and M.A. Cheever Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin. Cancer Res. 5 1996 1289 1297
22. M.L. Disis, T.A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M.A. Cheever, K.L. Knutson, and K. Shiffmann Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J. Clin. Oncol. 20 2002 2624 2632
23. C.M. zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells J. Immunol. 167 2001 1712 1719
24. N. Stivaktakis, K. Nikou, Z. Panagi, A. Beletsi, L. Leondiadis, and K. Avgoustakis PLA and PLGA microspheres of beta-galactosidase: effect of formulation factors on protein antigenicity and immunogenicity J. Biomed. Mater. Res. 70A 2004 139 148
25. D.T. O'Hagan, H. Jeffry, and S.S. Davis Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles Vaccine 11 1993 965 969
26. Y. Men, C. Thomasin, H.P. Merkle, B. Gander, and G. Corradin A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide Vaccine 13 1995 683 689
27. Y. Men, B. Gander, H.P. Merkle, and G. Corradin Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres Vaccine 14 1996 1442 1450
28. M. Igartua, R.M. Hernandez, A. Esquisabel, A.R. Gascon, M.B. Calvo, and J.L. Pedraz Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres J. Control. Release 56 1998 63 73
29. J.E. Rosas, J.L. Pedraz, R.M. Hernandez, A.R. Gascon, M. Igartua, F. Guzman, R. Rodriguez, J. Cortes, and M.E. Patarroyo Remarkably high antibody levels and protection against P. Falciparum malaria in Aotus monkeys after a single immunization of SPf66 encapsulated in PLGA microspheres Vaccine 20 2002 1707 1710
30. D.F. Nixon, C. Hioe, P. Chen, Z. Bian, P. Kuebler, M.L. Li, H. Qiu, X.M. Li, M. Singh, J. Richardson, P. MaGee, T. Zamb, W. Koff, C.Y. Wang, and D. O'Hagan Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity Vaccine 14 1996 1523 1530
31. C.D. Partidos, P. Vohra, D. Jones, G. Farrar, and M.W. Steward CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles J. Immunol. Methods 206 1997 143 151
32. K.D. Newman, D.L. Sosnowski, G.S. Kwon, and J. Samuel Delivery of MUC1 Mucin peptide by poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses J. Pharm. Sci. 87 1998 1421 1427
33. H.C. Ertl, I. Varga, Z.Q. Xiang, K. Kaiser, L. Stephens, and L. Otvos Jr. Poly (dl-lactide-co-glycolide) microspheres as carriers for peptide vaccines Vaccine 14 1996 879 885
34. D.T. O'Hagan, G.S. Ott, and G. Van Nest Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles Mol. Med. Today 3 1997 69 75
35. S. Lofthouse Immunological aspects of controlled antigen delivery Adv. Drug Deliv. Rev. 54 2002 863 870
36. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J. Exp. Med. 181 1995 2109 2117
37. L. Leondiadis, E. Livaniou, I. Vassiliadou, N. Ferderigos, D.S. Ithakissios, and GP. Evangelatos Development of specific anti-thymosin β10 antipeptide antibodies for application in immunochemical techniques Peptides 17 1996 1091 1096
38. G.B. Fields, and R.L. Noble Solid phase synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids Int. J. Pept. Protein Res. 35 1990 161 214
39. R. Bodmeier, and J.W. McGinity Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique: I. Methods and morphology J. Microencapsul 4 1987 279 288
40. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk Measurement of protein using bicinchoninic acid Anal. Biochem. 150 1985 76 85
41. T.N. Bullock, D.W. Mullins, T.A. Colella, and V.H. Engelhard Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice J. Immunol. 167 2001 5824 5831
42. C. Lotz, E.A. Ferreira, I. Drexler, S.A. Mutallib, C. Huber, G. Sutter, and M. Theobald Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man Int. J. Cancer 108 2004 571 579
43. J. Ronnelid, and L. Klareskog A comparison between ELISPOT methods for the detection of cytokine producing cells: greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes J. Immunol. Methods 200 1997 17 26
44. A. Schmittel, U. Keilholz, S. Bauer, U. Kuhne, S. Stevanovic, E. Thiel, and C. Scheibenbogen Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins J. Immunol. Methods 247 2001 17 24
45. G. Pawelec, R.C. Rees, R. Kiessling, A. Madrigal, A. Dodi, C. Baxevanis, C. Gambacorti-Passerini, G. Masucci, and J. Zeuthen Cells and cytokines in immunotherapy and gene therapy of cancer Crit. Rev. Oncog. 10 1999 83 127
46. MF. Mescher Surface contact requirements for activation of cytotoxic T lymphocytes J. Immunol. 149 1992 2402 2405
47. R.A. Kemp, and F. Ronchese Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity J. Immunol. 167 2001 6497 6502
48. C.N. Baxevanis, I.F. Voutsas, O.E. Tsitsilonis, A.D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor J. Immunol. 164 2000 3902 3912
49. C. Sedlik, E. Deriaud, and C. Leclerc Lack of Th1 or Th2 polarization of CD4+ T cell response induced by particulate antigen targeted to phagocytic cells Int. Immunol. 9 1997 91 103
50. M.J. Alonso, R.K. Gupta, C. Min, G.R. Siber, and R. Langer Biodegradable microspheres as controlled-release tetanus toxoid delivery systems Vaccine 12 1994 299 306
51. M. Morlock, H. Koll, G. Winter, and T. Kissel Microencapsulation of rh-erythropoietin, using biodegradable poly (d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients Eur. J. Pharm. Biopharm. 43 1997 29 36
52. J.L. Cleland, and A.J.S. Jones Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres Pharm. Res. 13 1996 1464 1474
53. M. Van de Weert, W.E. Hennink, and W. Jiskoot Protein instability in poly (lactic-co-glycolic acid) microparticles Pharm. Res. 13 1996 1464 1474